Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Galmed Pharmaceuticals Ltd’s stock clocked out at $1.28, up 3.23% from its previous closing price of $1.24. In other words, the price has increased by $3.23 from its previous closing price. On the day, 0.5 million shares were traded.
Ratios:
To gain a deeper understanding of GLMD’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.42 and its Current Ratio is at 7.42. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley FBR on May 22, 2020, Downgraded its rating to Neutral and sets its target price to $8 from $11 previously.
On February 04, 2020, Craig Hallum started tracking the stock assigning a Buy rating and target price of $18.
Stock Price History:
Over the past 52 weeks, GLMD has reached a high of $23.80, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is -20.60%, while the 200-Day Moving Average is calculated to be -58.84%.
Shares Statistics:
A total of 2.26M shares are outstanding, with a floating share count of 2.22M. Insiders hold about 1.72% of the company’s shares, while institutions hold 9.39% stake in the company.
